Newsroom
Sorted by: Latest
-
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will present new long-term AVMAPKI™ FAKZYNJA™ combination therapy (avutometinib capsules; defactinib tablets) data from the Phase 2 RAMP 201 clinical trial at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women’s Cancers. Additional abstracts accepted for presentation will also be shar...
-
JPMorganChase to Host First-Quarter 2026 Earnings Call
NEW YORK--(BUSINESS WIRE)--As previously announced, JPMorgan Chase & Co. (NYSE: JPM) (“JPMorganChase” or the “Firm”) will host a conference call to review first-quarter 2026 financial results on Tuesday, April 14, 2026 at 8:30 a.m. (ET). The results are scheduled to be released at approximately 7:00 a.m. (ET). The live audio webcast and presentation slides will be available on www.jpmorganchase.com under Investor Relations, Events & Presentations. JPMorganChase will notify the public th...
-
Fifth Third Bancorp Announces Cash Dividends
CINCINNATI--(BUSINESS WIRE)--Today, Fifth Third Bancorp announced the declaration of cash dividends on its common shares, Series H preferred shares, Series I preferred shares, Series J preferred shares, Series K preferred shares, Series M preferred shares, and Class B Series A preferred shares. Fifth Third Bancorp (Nasdaq: FITB) today declared a cash dividend on its common shares of $0.40 per share for the first quarter of 2026. The dividend is payable on April 15, 2026 to shareholders of recor...
-
Kinaxis optimise sa chaîne d'approvisionnement à grande échelle grâce à l'IA de NVIDIA
OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX : KXS), leader mondial de l'orchestration de la chaîne d'approvisionnement, a annoncé aujourd'hui une nouvelle étape importante dans l'optimisation à grande échelle des chaînes d'approvisionnement au sein de la plateforme Kinaxis Maestro™. Maestro assure déjà une optimisation haute performance des chaînes d'approvisionnement mondiales complexes, et Kinaxis renforce désormais son leadership grâce à l'accélération GPU alimentée par NVIDIA cuOpt...
-
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating botensilimab (BOT) in combination with balstilimab (BAL) in first-line microsatellite stable colorectal cancer (MSS CRC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 18–23 in San Diego, CA. The BBoPCO study (Botensilimab and Balstilimab Optimization...
-
Resumen: 1500 millones de mujeres no se someten a pruebas preventivas imprescindibles, a pesar del aumento de las tasas de detección a nivel internacional
WASHINGTON--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), empresa líder internacional en salud de la mujer, ha publicado hoy unos datos que revelan que, aunque las pruebas de detección de algunas enfermedades han aumentado entre las mujeres de todo el mundo, sigue existiendo una gran brecha en materia de cribado. Más de la mitad de las mujeres y niñas de 15 años o más, lo que supone aproximadamente 1 500 millones de mujeres, no se sometieron a pruebas de detección de cáncer, hipertensión, diab...
-
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company’s internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17-22 in San Diego, California. These next-generation candidates include: zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (A...
-
Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK‑012 in First‑Line Nonsquamous NSCLC with Features of Immunotherapy Resistance
MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced that updated clinical and translational data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, will be presented in an oral presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place in San Diego, CA from April 17 - 22, 2026. In this now fully enrolled study, STK-012 is being evaluated in combinatio...
-
UnitedHealth Group Announces Earnings Release Date
--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) will release its first quarter 2026 financial results on Tuesday, April 21, 2026, before the market opens, and will host a teleconference at 8:00 a.m. ET with analysts and investors. This call will be webcast on the Investor Relations page of the company’s website (www.unitedhealthgroup.com). The replay will be available through May 5, 2026, on the website. About UnitedHealth Group UnitedHealth Group (NYSE: UNH) is a health care and well-being c...
-
1,5 Milliarden Frauen verpassen wichtige Vorsorgeuntersuchungen – trotz weltweit steigender Screening-Raten
WASHINGTON--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), ein weltweit führendes Unternehmen im Bereich der Frauengesundheit, veröffentlichte heute Daten, aus denen hervorgeht, dass zwar die Zahl der Vorsorgeuntersuchungen bei Frauen weltweit gestiegen ist, jedoch nach wie vor eine große Lücke im Zugang zu Vorsorgeuntersuchungen besteht. Über die Hälfte der Frauen und Mädchen ab 15 Jahren – schätzungsweise 1,5 Milliarden Frauen – wurden im vergangenen Jahr nicht auf Krebs, Bluthochdruck, Diabe...